Phase II trial of carboplatin or iproplatin in cervical cancer


From July 1984 to November 1987, 89 patients with recurrent measurable squamous-cell cancer of the uterine cervix were randomized in a single institution to receive treatment with either carboplatin (CBDCA) or iproplatin (CHIP). Objective response rates were similar: 2 complete regressions (CRs) and 10 partial regressions (PRs) were recorded both in the 46… (More)
DOI: 10.1007/BF00685695


6 Figures and Tables